These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment. Bogousslavsky J; Paciaroni M; Gallai V Clin Exp Hypertens; 2002; 24(7-8):603-10. PubMed ID: 12450235 [TBL] [Abstract][Full Text] [Related]
7. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Hankey GJ Cerebrovasc Dis; 2004; 17 Suppl 3():11-6. PubMed ID: 14730253 [TBL] [Abstract][Full Text] [Related]
8. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
10. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423 [TBL] [Abstract][Full Text] [Related]
11. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Stringer KA Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186 [TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome. Latour-Pérez J Ann Pharmacother; 2001 Apr; 35(4):472-9. PubMed ID: 11302412 [TBL] [Abstract][Full Text] [Related]
13. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519 [TBL] [Abstract][Full Text] [Related]
14. Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke. Yang M; Huo X; Miao Z; Wang Y Drugs; 2019 Apr; 79(5):515-529. PubMed ID: 30838514 [TBL] [Abstract][Full Text] [Related]
15. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. De Luca G; Savonitto S; van't Hof AW; Suryapranata H Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890 [TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Mak KH; Effron MB; Moliterno DJ Drugs Aging; 2000 Mar; 16(3):179-87. PubMed ID: 10803858 [TBL] [Abstract][Full Text] [Related]
19. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors. Dobesh PP; Latham KA Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642 [TBL] [Abstract][Full Text] [Related]
20. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]